{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Schievink B"],"funding":["NIA NIH HHS"],"pagination":["758-68"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7735387"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(7)"],"pubmed_abstract":["<h4>Background</h4>A recent phase II clinical trial (Reducing Residual Albuminuria in Subjects with Diabetes and Nephropathy with AtRasentan trial and an identical trial in Japan (RADAR/JAPAN)) showed that the endothelin A receptor antagonist atrasentan lowers albuminuria, blood pressure, cholesterol, hemoglobin, and increases body weight in patients with type 2 diabetes and nephropathy. We previously developed an algorithm, the Parameter Response Efficacy (PRE) score, which translates short-term drug effects into predictions of long-term effects on clinical outcomes.<h4>Design</h4>We used the PRE score on data from the RADAR/JAPAN study to predict the effect of atrasentan on renal and heart failure outcomes.<h4>Methods</h4>We performed a post-hoc analysis of the RADAR/JAPAN randomized cli"],"journal":["European journal of preventive cardiology"],"pubmed_title":["Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers."],"pmcid":["PMC7735387"],"funding_grant_id":["R01 AG018915","R01 AG045551"],"pubmed_authors":["Toto R","Kitzman DW","Parving HH","Schievink B","de Zeeuw D","Perkovic V","Hoekman J","Coll B","Andress D","Tobe S","Smink PA","Kohan D","Makino H","Lambers Heerspink HJ","Brennan JJ","Remuzzi G","Correa-Rotter R","Hou FF"],"additional_accession":[]},"is_claimable":false,"name":"Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.","description":"<h4>Background</h4>A recent phase II clinical trial (Reducing Residual Albuminuria in Subjects with Diabetes and Nephropathy with AtRasentan trial and an identical trial in Japan (RADAR/JAPAN)) showed that the endothelin A receptor antagonist atrasentan lowers albuminuria, blood pressure, cholesterol, hemoglobin, and increases body weight in patients with type 2 diabetes and nephropathy. We previously developed an algorithm, the Parameter Response Efficacy (PRE) score, which translates short-term drug effects into predictions of long-term effects on clinical outcomes.<h4>Design</h4>We used the PRE score on data from the RADAR/JAPAN study to predict the effect of atrasentan on renal and heart failure outcomes.<h4>Methods</h4>We performed a post-hoc analysis of the RADAR/JAPAN randomized cli","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 May","modification":"2026-05-03T08:14:41.025Z","creation":"2021-02-20T12:24:38Z"},"accession":"S-EPMC7735387","cross_references":{"pubmed":["26229089"],"doi":["10.1177/2047487315598709"]}}